Acute Respiratory Distress SyndromeDeVENTNCT04115709
Decision Support System to Evaluate VENTilation in ARDS
A study testing Beacon Caresystem device with advice and Beacon Caresystem device without advice activated in people with Acute Respiratory Distress Syndrome, run by Imperial College London at 3 sites in 3 countries.
Trial summary
Patients with Acute Respiratory Distress Syndrome (ARDS) residing in the intensive care unit (ICU) often require support for their breathing from a mechanical ventilator to provide adequate gas exchange, and although it is life-saving in this setting, it is also known to contribute to the morbidity and mortality in… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Acute Respiratory Distress Syndrome
- What is being tested?
- Beacon Caresystem device with advice and Beacon Caresystem device without advice activated
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 95 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 19 Mar 2020to 30 Aug 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Invasive mechanical ventilation.
- Within 1 week of a known clinical insult or new or worsening respiratory symptoms
- Chest radiograph with bilateral infiltrates consistent with evidence of pulmonary oedema but not fully explained by cardiac failure.
- Hypoxaemia as defined by PaO2/FiO2 of ≤ 300mmHg (or ≤ 40kPa) (pre-ECMO PaO2/FiO2 will be used should patient be placed on extracorporeal support).
- 18 years or older
- Able to consent
- Have mental capacity
Who cannot join
- Age < 18 years old.
- The absence of an arterial catheter for blood sampling at study start.
- Consent declined.
- Over 7 days of mechanical ventilation.
- Treatment withdrawal imminent within 24 hours.
- DNAR (Do Not Attempt Resuscitation) order in place
Show all 17Show fewer
- Severe chronic respiratory disease requiring domiciliary ventilation (except for sleep disordered breathing)
- Veno-Arterial ECMO
- Healthy Volunteer Sample collection:
- Blood borne viruses: HIV, Hep B, Hep C
- Blood taken in the last 7 days
- Under doctor for investigation
- Haematological disease
- Currently suffers from infection
- Needle phobia
- Problems with veins / vessels
- Refusal
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
United Kingdom1 site
Imperial College London, Royal Brompton Hospital campus
London, SW3 6NP
About this study
Official title: Decision Support System to Evaluate VENTilation in ARDS (DeVENT)
Patients with Acute Respiratory Distress Syndrome (ARDS) residing in the intensive care unit (ICU) often require support for their breathing from a mechanical ventilator to provide adequate gas exchange, and although it is life-saving in this setting, it is also known to contribute to the morbidity and mortality in the condition.
Mechanical ventilation delivers a volume and pressure of gas for each breath and can vary oxygen levels. Selecting the correct oxygen, pressure and volume levels is important, as incorrect levels can harm the patient, and result in an increased time connected to the ventilator.
Read more
Recently, a system has been developed (the Beacon Caresystem) which advises the healthcare practitioner by the bedside as to how to best set the ventilator. This system is based on mathematics which describes the patients disease and may therefore provide ventilator settings which better suit the individual.
The purpose of this study is to compare mechanical ventilation in ARDS patients following advice from the Beacon Caresystem to that of standard care to investigate whether the use of the system results in improved ventilation in all severities and phases of ARDS and thus reducing morbidity in ARDS. The investigators plan to recruit 110 patients (50 in the UK and 30 in each of the other 2 sites). The study also aims to examine the biological and physiological factors that determine the worsening of ARDS and the processes involved in recovery from ARDS with the aim to develop new therapies to help detect the condition and improve recovery.
The investigators will utilise all raw data will be collected from the Beacon Caresystem to physiologically characterise the progression and resolution phases of ARDS.
Additionally blood and Urine samples will be taken from healthy volunteers (100 in total) as a control comparison group for the biological analyses carried out in the DeVENT study.
Read the detailed description
The study is a randomised control trial, comparing the effects of mechanical ventilation in ARDS provided as standard care, with mechanical ventilation set according to the advice of the Beacon Care system. The study will compare if the use of the system results in a better application of PEEP and driving pressure across all severities and phases of ARDS.
The broad timeframe for the study is as follows. The study will be conducted at three sites. Two of these sites are outside the UK, one in France and one in Italy.
The systems will be delivered and installed starting September/October 2019 in the UK site, followed by France and Austria in November 2019. A one month period of training will then follow where all doctors and nurses involved in using the system will be trained. During this period none of the systems advice will be applied. This training will be supported by study partners, and nurses trained as super users of the system, by Mermaid Care A/S, the company producing the system, and by project investigators who have previously conducted studies using the system.
Patient inclusion and data collection will be performed at in the UK sites over a 15 month period from start October 2019 to January 2020. In both European sites, inclusion and data collection will be performed over a 12 month period from start January 2020 to December 2020. Final data analysis and report writing will be performed by March 2021.
For all study sites, all adult patients diagnosed with ARDS in the cardio-thoracic intensive care unit (ICU) undergoing mechanical ventilation will be considered to see if they are eligible for the study.
Patients will only be considered eligible if they are Within 7 days of an acute and potentially reversible episode of acute respiratory failure, their chest radiograph with bilateral infiltrates is consistent with evidence of pulmonary oedema but not fully explained by cardiac failure and they present with hypoxaemia. In addition, patients are not considered eligible due to being aged under 18, not having an arterial catheter for blood sampling at study start, consent declined, over 7 days of mechanical ventilation, treatment withdrawal imminent within 24 hours, Do Not Attempt Resuscitation order in place and for having a severe chronic respiratory disease requiring domiciliary ventilatioin. For each patient, if identified as eligible, advice to participate in the study will be sought.
Critically ill patients are and often unconscious and may not be able to grant consent. Therefore, the Patient Informed Sheet (PIS) and Consent Form will be requested from a third party acting as a consultee; in most cases this person will be a Personal Consultee, who is someone who knows the person lacking capacity and is able to advise the researcher about that person's wishes and feelings in relation to the project and whether they should join the research. This person must be interested in the welfare of the patient in a personal capacity, not in a professional capacity or for remuneration and will mostly likely be family member, carer or friend, etc. Where the personal consultee is not available on site, the researcher may contact the personal consultee by telephone and seek verbal advice. The verbal agreement will be recorded in the telephone consultee declaration form. The telephone consultee declaration form will be signed by a second member of staff who has witnessed the telephone advice. A copy of the PIS will be emailed to the personal consultee.
Where no Personal Consultee is available, the researcher will nominate a professional person to assist in determining the participation of a person who lacks capacity. A Nominated Professional Consultee is someone who will be appointed by the researcher to advise the researcher about the person's (who lacks capacity) wishes and feelings in relation to the project and whether they should join the research. An independent clinician not treating the patient will be asked to be the nominated consultee. A patient information sheet will be distributed immediately following the patient being identified as eligible for the study.
The study investigators will ask the patient if they can use their existing hospital records. Without their consent, no additional information about the patient will be collected for the purposes of the study. However, to maintain integrity of the randomised trial, all information collected up to that time will still be used and analysed as part of the study.
If consent is obtained and the patient is still eligible, then they will be randomly allocated to one of two groups. This random allocation will be performed according to the randomisation template with random block allocation.
If the patient is allocated to the standard care group then all care will be according to usual practice. If the patient is allocated to the Beacon group, mechanical ventilation will be set with advice from the system. In either case, the study ends for the individual patient either with successful transfer of the patient to another department, or patient death. All other care will be according to usual practice.
110 patients will be included in the study, with 55 patients in each of the groups. 55 patients per group will allow to detect a difference of 3cmH2O in driving pressure between the groups with 90% power and a two sided alpha of 0.05 assuming a control group driving pressure of 15 cmH2O with a standard deviation of 2.5 cmH2O and including a 40% dropout. The investigators have used data from the MIMIC dataset (as published in Serpo Neto et al) for the estimation of the driving pressure. In view of the longitudinal analysis, loss to follow up has taken account of an average mortality of 34% and a 6% drop out.
- Conditions
- Acute Respiratory Distress Syndrome
- Being tested
- Beacon Caresystem device with advice, Beacon Caresystem device without advice activated
- Keywords
- Acute Respiratory Distress Syndrome, Intensive Care, Device, Beacon Caresystem©, Ventilation
- Medical subject headings
- Respiratory Distress Syndrome, Respiratory Aspiration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beacon Caresystem device with adviceDevice
Beacon Caresystem device provides ventilator settings advice to Doctors
Beacon Caresystem device without advice activatedDevice
Beacon Caresystem device does not give ventilator settings advice
| Study group | Role | What they receive |
|---|---|---|
| Intervention: Device attached with advice activated | Experimental | Beacon Caresystem device will be attached to the patients and its ventilator advice will be activated. Receives: Device: Beacon Caresystem device with advice |
| Control: standard care with device attached without advice | Active comparator | Beacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated. Receives: Device: Beacon Caresystem device without advice activated |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average Driving pressure delivery by the mechanical ventilator
To assess the average driving pressure delivered by the mechanical ventilator over the period of time when ARDS ventilation management is advised by the Beacon Caresystem as compared to standard care.
Measured: 18 months
Secondary outcomes (37)
Daily Average physiological status - oxygenation (SpO2)
- Daily average physiological status defined as daily averages of measured values of oxygenation (SpO2)
Measured: 18 months
Daily Average physiological status - end-tidal CO2 fraction (FE'CO2)
- Daily average physiological status defined as daily averages of measured values end-tidal CO2 fraction (FE'CO2)
Measured: 18 months
Daily Average physiological status - metabolism (VO2, VCO2)
- Daily average physiological status defined as daily averages of measured values of metabolism (VO2, VCO2)
Measured: 18 months
Daily Average physiological status - ventilation (respiratory rate)
- Daily average physiological status defined as daily averages of measured values of ventilation (respiratory rate)
Measured: 18 months
Daily Average physiological status - ventilation (tidal volume)
- Daily average physiological status defined as daily averages of measured values of ventilation (tidal volume)
Measured: 18 months
Daily Average physiological status - ventilation (anatomical dead space)
- Daily average physiological status defined as daily averages of measured values of ventilation (anatomical dead space)
Measured: 18 months
Daily Average physiological status - pulmonary mechanisms (mean airway pressure)
- Daily average physiological status defined as daily averages of measured values of pulmonary mechanisms (mean airway pressure)
Measured: 18 months
Daily Average physiological status
- Daily average physiological status defined as daily averages of measured values of pulmonary mechanisms (respiratory system compilance)
Measured: 18 months
Daily Average physiological status
- Daily average physiological status defined as daily averages of measured values of ventilator settings
Measured: 18 months
Daily Average physiological status - PaO2/FiO2
- Daily average physiological status defined as daily averages of measured values of PaO2/FiO2
Measured: 18 months
Daily Average physiological status - shunt fraction
- Daily average physiological status defined as daily averages of measured values of shunt fraction
Measured: 18 months
Daily Average physiological status - end-expiratory lung volume
- Daily average physiological status defined as daily averages of measured values of end-expiratory lung volume over time as continuously measured by the Beacon system
Measured: 18 months
Daily average calculated delivered pressure over time
- Daily average calculated delivered pressure over time, for periods of spontaneous breathing.
Measured: 18 months
Daily average calculated mechanical power over time
- Daily average calculated mechanical power over time
Measured: 18 months
Daily average calculated oxygenation index over time
- Daily average calculated oxygenation index over time
Measured: 18 months
Daily average ventilatory ratio over time
- Daily average ventilatory ratio over time
Measured: 18 months
Incidence and duration of proning events and pre- and post- respiratory physiology
- Incidence and duration of proning events and pre- and post- respiratory physiology
Measured: 18 months
Ventilator free days at 28 days.
- Ventilator free days at 28 days.
Measured: 28 days
Composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors
- Composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors
Measured: 28 days
Time from control mode to support mode
- Time from control mode to support mode
Measured: 18 months
Proportion of breaths dysyncronous with the ventilator
- Proportion of breaths dysyncronous with the ventilator
Measured: 18 months
Number of changes in ventilator settings per day
- Number of changes in ventilator settings per day
Measured: 18 months
Percentage of time in control mode ventilation
- % of time in control mode ventilation
Measured: 18 months
Percentage of time in support mode ventilation
- % of time in support mode ventilation
Measured: 18 months
Total duration of mechanical ventilation
- Total duration of mechanical ventilation
Measured: 18 months
Changes in tidal volume over time
- Changes in tidal volume over time
Measured: 18 months
Changes in Positive End Expiratory Pressure (PEEP) setting over time
- Changes in Positive End Expiratory Pressure (PEEP) setting over time
Measured: 18 months
Daily and cumulative fluid balance.
- Daily and cumulative fluid balance.
Measured: 18 months
Timing, incidence and duration of ECMO
- Timing, incidence and duration of ECMO
Measured: 18 months
Timing, incidence and duration of neuromuscular blockade
- Timing, incidence and duration of neuromuscular blockade
Measured: 18 months
Mortality at 28 days
Mortality at 28 days
Measured: 28 days
Mortality at 6 months
Mortality at 6 months
Measured: 6 months
Mortality at 1 year
Mortality at 1 year
Measured: 1 year
Organ failure assessment (SOFA) score and/or delta SOFA
- Organ failure free days in the first 28 days, assessed using the sequential organ failure assessment (SOFA) score and/or delta SOFA
Measured: 28 days
Number of patients with ventilation related complications
Number of patients with ventilation related complications e.g. pneumothorax and/or pneumomediastinum
Measured: 18 months
Device malfunction event rate
- Device malfunction event rate
Measured: 18 months
Number of times the advice from the Beacon system is followed
- Number of times the advice from the Beacon system is followed
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2019
- Study start19 Mar 2020
- Primary completion30 Mar 2021
- Study completion30 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Acute Respiratory Distress SyndromeStudies of the same condition, open and under way.
- More trials run by Imperial College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imperial College London
- Sponsor type
- University, hospital or other
- Collaborators
- European Commission, Mermaid A/C, Aalborg University, Université d'Auvergne, Medical University of Vienna, Sorbonne University, Queen's University, Belfast
- Responsible party
- Sponsor
- Investigators
- Brijesh Patel, MBBS MRCP FRCA FFICM PhD, Principal investigator, Imperial College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04115709
- Sponsor's protocol ID
- 19IC5421
- Acronym
- DeVENT
- Status last verified
- Sep 2021
- First submitted
- 2 Sep 2019
- Last updated
- 16 Sep 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Patel BV, Mumby S, Johnson N, Handslip R, Patel S, Lee T, Andersen MS, Falaschetti E, Adcock IM, McAuley DF, Takata M, Staudinger T, Karbing DS, Jabaudon M, Schellongowski P, Rees SE; DeVENT Study Group. A randomized control trial evaluating the advice of a physiological-model/digital twin-based decision support system on mechanical ventilation in patients with acute respiratory distress syndrome. Front Med (Lausanne). 2024 Oct 30;11:1473629. doi: 10.3389/fmed.2024.1473629. eCollection 2024.
PubMed 39540041Patel B, Mumby S, Johnson N, Falaschetti E, Hansen J, Adcock I, McAuley D, Takata M, Karbing DS, Jabaudon M, Schellengowski P, Rees SE; DeVENT study group. Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol. Trials. 2022 Jan 17;23(1):47. doi: 10.1186/s13063-021-05967-2.
PubMed 35039050
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Decision Support System to Evaluate VENTilation in ARDS (DeVENT)
- ClinicalTrials.gov ID
- NCT04115709
- Acronym / sponsor ID
- DeVENT / 19IC5421
- Conditions
- Acute Respiratory Distress Syndrome
- Keywords
- Acute Respiratory Distress Syndrome, Intensive Care, Device, Beacon Caresystem©, Ventilation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 95 participants (actual)
- Lead sponsor
- Imperial College LondonUniversity, hospital or other
- Collaborators
- European Commission, Mermaid A/C, Aalborg University, Université d'Auvergne, Medical University of Vienna, Sorbonne University, Queen's University, Belfast
- Study start
- 19 Mar 2020 (actual)
- Primary completion
- 30 Mar 2021 (actual)
- Study completion
- 30 Aug 2021 (actual)
- First posted
- 4 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with Acute Respiratory Distress Syndrome (ARDS) residing in the intensive care unit (ICU) often require support for their breathing from a mechanical ventilator to provide adequate gas exchange, and although it is life-saving in this setting, it is also known to contribute to the morbidity and mortality in the condition.
Mechanical ventilation delivers a volume and pressure of gas for each breath and can vary oxygen levels. Selecting the correct oxygen, pressure and volume levels is important, as incorrect levels can harm the patient, and result in an increased time connected to the ventilator.
Recently, a system has been developed (the Beacon Caresystem) which advises the healthcare practitioner by the bedside as to how to best set the ventilator. This system is based on mathematics which describes the patients disease and may therefore provide ventilator settings which better suit the individual.
The purpose of this study is to compare mechanical ventilation in ARDS patients following advice from the Beacon Caresystem to that of standard care to investigate whether the use of the system results in improved ventilation in all severities and phases of ARDS and thus reducing morbidity in ARDS. The investigators plan to recruit 110 patients (50 in the UK and 30 in each of the other 2 sites). The study also aims to examine the biological and physiological factors that determine the worsening of ARDS and the processes involved in recovery from ARDS with the aim to develop new therapies to help detect the condition and improve recovery.
The investigators will utilise all raw data will be collected from the Beacon Caresystem to physiologically characterise the progression and resolution phases of ARDS.
Additionally blood and Urine samples will be taken from healthy volunteers (100 in total) as a control comparison group for the biological analyses carried out in the DeVENT study.
Detailed description
The study is a randomised control trial, comparing the effects of mechanical ventilation in ARDS provided as standard care, with mechanical ventilation set according to the advice of the Beacon Care system. The study will compare if the use of the system results in a better application of PEEP and driving pressure across all severities and phases of ARDS.
The broad timeframe for the study is as follows. The study will be conducted at three sites. Two of these sites are outside the UK, one in France and one in Italy.
The systems will be delivered and installed starting September/October 2019 in the UK site, followed by France and Austria in November 2019. A one month period of training will then follow where all doctors and nurses involved in using the system will be trained. During this period none of the systems advice will be applied. This training will be supported by study partners, and nurses trained as super users of the system, by Mermaid Care A/S, the company producing the system, and by project investigators who have previously conducted studies using the system.
Patient inclusion and data collection will be performed at in the UK sites over a 15 month period from start October 2019 to January 2020. In both European sites, inclusion and data collection will be performed over a 12 month period from start January 2020 to December 2020. Final data analysis and report writing will be performed by March 2021.
For all study sites, all adult patients diagnosed with ARDS in the cardio-thoracic intensive care unit (ICU) undergoing mechanical ventilation will be considered to see if they are eligible for the study.
Patients will only be considered eligible if they are Within 7 days of an acute and potentially reversible episode of acute respiratory failure, their chest radiograph with bilateral infiltrates is consistent with evidence of pulmonary oedema but not fully explained by cardiac failure and they present with hypoxaemia. In addition, patients are not considered eligible due to being aged under 18, not having an arterial catheter for blood sampling at study start, consent declined, over 7 days of mechanical ventilation, treatment withdrawal imminent within 24 hours, Do Not Attempt Resuscitation order in place and for having a severe chronic respiratory disease requiring domiciliary ventilatioin. For each patient, if identified as eligible, advice to participate in the study will be sought.
Critically ill patients are and often unconscious and may not be able to grant consent. Therefore, the Patient Informed Sheet (PIS) and Consent Form will be requested from a third party acting as a consultee; in most cases this person will be a Personal Consultee, who is someone who knows the person lacking capacity and is able to advise the researcher about that person's wishes and feelings in relation to the project and whether they should join the research. This person must be interested in the welfare of the patient in a personal capacity, not in a professional capacity or for remuneration and will mostly likely be family member, carer or friend, etc. Where the personal consultee is not available on site, the researcher may contact the personal consultee by telephone and seek verbal advice. The verbal agreement will be recorded in the telephone consultee declaration form. The telephone consultee declaration form will be signed by a second member of staff who has witnessed the telephone advice. A copy of the PIS will be emailed to the personal consultee.
Where no Personal Consultee is available, the researcher will nominate a professional person to assist in determining the participation of a person who lacks capacity. A Nominated Professional Consultee is someone who will be appointed by the researcher to advise the researcher about the person's (who lacks capacity) wishes and feelings in relation to the project and whether they should join the research. An independent clinician not treating the patient will be asked to be the nominated consultee. A patient information sheet will be distributed immediately following the patient being identified as eligible for the study.
The study investigators will ask the patient if they can use their existing hospital records. Without their consent, no additional information about the patient will be collected for the purposes of the study. However, to maintain integrity of the randomised trial, all information collected up to that time will still be used and analysed as part of the study.
If consent is obtained and the patient is still eligible, then they will be randomly allocated to one of two groups. This random allocation will be performed according to the randomisation template with random block allocation.
If the patient is allocated to the standard care group then all care will be according to usual practice. If the patient is allocated to the Beacon group, mechanical ventilation will be set with advice from the system. In either case, the study ends for the individual patient either with successful transfer of the patient to another department, or patient death. All other care will be according to usual practice.
110 patients will be included in the study, with 55 patients in each of the groups. 55 patients per group will allow to detect a difference of 3cmH2O in driving pressure between the groups with 90% power and a two sided alpha of 0.05 assuming a control group driving pressure of 15 cmH2O with a standard deviation of 2.5 cmH2O and including a 40% dropout. The investigators have used data from the MIMIC dataset (as published in Serpo Neto et al) for the estimation of the driving pressure. In view of the longitudinal analysis, loss to follow up has taken account of an average mortality of 34% and a 6% drop out.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention: Device attached with advice activated | Experimental | Device: Beacon Caresystem device with adviceBeacon Caresystem device will be attached to the patients and its ventilator advice will be activated. |
| Control: standard care with device attached without advice | Active comparator | Device: Beacon Caresystem device without advice activatedBeacon Caresystem device will be attached to the patients however the ventilator advice will be deactivated. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Invasive mechanical ventilation.
- Within 1 week of a known clinical insult or new or worsening respiratory symptoms
- Chest radiograph with bilateral infiltrates consistent with evidence of pulmonary oedema but not fully explained by cardiac failure.
- Hypoxaemia as defined by PaO2/FiO2 of ≤ 300mmHg (or ≤ 40kPa) (pre-ECMO PaO2/FiO2 will be used should patient be placed on extracorporeal support).
- 18 years or older
Key exclusion criteria (17 listed)
- Age < 18 years old.
- The absence of an arterial catheter for blood sampling at study start.
- Consent declined.
- Over 7 days of mechanical ventilation.
- Treatment withdrawal imminent within 24 hours.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beacon Caresystem device with adviceBeacon Caresystem device provides ventilator settings advice to Doctors | Device | Intervention: Device attached with advice activated |
| Beacon Caresystem device without advice activatedBeacon Caresystem device does not give ventilator settings advice | Device | Control: standard care with device attached without advice |
Primary outcome
Average Driving pressure delivery by the mechanical ventilator
Time frame: 18 months
To assess the average driving pressure delivered by the mechanical ventilator over the period of time when ARDS ventilation management is advised by the Beacon Caresystem as compared to standard care.
37 secondary outcomes
Daily Average physiological status - oxygenation (SpO2)
Time frame: 18 months
Daily Average physiological status - end-tidal CO2 fraction (FE'CO2)
Time frame: 18 months
Daily Average physiological status - metabolism (VO2, VCO2)
Time frame: 18 months
Daily Average physiological status - ventilation (respiratory rate)
Time frame: 18 months
Daily Average physiological status - ventilation (tidal volume)
Time frame: 18 months
Daily Average physiological status - ventilation (anatomical dead space)
Time frame: 18 months
Daily Average physiological status - pulmonary mechanisms (mean airway pressure)
Time frame: 18 months
Daily Average physiological status
Time frame: 18 months
Daily Average physiological status
Time frame: 18 months
Daily Average physiological status - PaO2/FiO2
Time frame: 18 months
Daily Average physiological status - shunt fraction
Time frame: 18 months
Daily Average physiological status - end-expiratory lung volume
Time frame: 18 months
Daily average calculated delivered pressure over time
Time frame: 18 months
Daily average calculated mechanical power over time
Time frame: 18 months
Daily average calculated oxygenation index over time
Time frame: 18 months
Daily average ventilatory ratio over time
Time frame: 18 months
Incidence and duration of proning events and pre- and post- respiratory physiology
Time frame: 18 months
Ventilator free days at 28 days.
Time frame: 28 days
Composite endpoint including any cause of death at 28 days and days free of mechanical ventilation within 28 days among survivors
Time frame: 28 days
Time from control mode to support mode
Time frame: 18 months
Proportion of breaths dysyncronous with the ventilator
Time frame: 18 months
Number of changes in ventilator settings per day
Time frame: 18 months
Percentage of time in control mode ventilation
Time frame: 18 months
Percentage of time in support mode ventilation
Time frame: 18 months
Total duration of mechanical ventilation
Time frame: 18 months
Changes in tidal volume over time
Time frame: 18 months
Changes in Positive End Expiratory Pressure (PEEP) setting over time
Time frame: 18 months
Daily and cumulative fluid balance.
Time frame: 18 months
Timing, incidence and duration of ECMO
Time frame: 18 months
Timing, incidence and duration of neuromuscular blockade
Time frame: 18 months
Mortality at 28 days
Time frame: 28 days
Mortality at 6 months
Time frame: 6 months
Mortality at 1 year
Time frame: 1 year
Organ failure assessment (SOFA) score and/or delta SOFA
Time frame: 28 days
Number of patients with ventilation related complications
Time frame: 18 months
Device malfunction event rate
Time frame: 18 months
Number of times the advice from the Beacon system is followed
Time frame: 18 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2021.
- Derived from this study: PubMed 39540041Patel BV, Mumby S, Johnson N, Handslip R, Patel S, Lee T, Andersen MS, Falaschetti E, Adcock IM, McAuley DF, Takata M, Staudinger T, Karbing DS, Jabaudon M, Schellongowski P, Rees SE; DeVENT Study Group. A randomized control trial evaluating the advice of a physiological-model/digital twin-based decision support system on mechanical ventilation in patients with acute respiratory distress syndrome. Front Med (Lausanne). 2024 Oct 30;11:1473629. doi: 10.3389/fmed.2024.1473629. eCollection 2024.
- Derived from this study: PubMed 35039050Patel B, Mumby S, Johnson N, Falaschetti E, Hansen J, Adcock I, McAuley D, Takata M, Karbing DS, Jabaudon M, Schellengowski P, Rees SE; DeVENT study group. Decision support system to evaluate ventilation in the acute respiratory distress syndrome (DeVENT study)-trial protocol. Trials. 2022 Jan 17;23(1):47. doi: 10.1186/s13063-021-05967-2.
- Individual participant dataSharing planned: No
Related trials for Acute Respiratory Distress Syndrome
Not yet recruitingObservational study
Diaphragm Response in Elderly for Acute Monitoring
Acute Dyspnea, Acute Respiratory Failure
RecruitingPhase 3
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Recruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
RecruitingObservational study
Pulmonary Immune Cell-microbiome Interactions in ARDS
ARDS, Human
RecruitingPhase 2
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
Acute Respiratory Distress Syndrome, Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Brijesh Patel, MBBS MRCP FRCA FFICM PhD principal investigator
Imperial College London
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Beacon Caresystem device with advice and Beacon Caresystem device without advice activated in people with Acute Respiratory Distress Syndrome, run by Imperial College London at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Austria, France, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average Driving pressure delivery by the mechanical ventilator (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04115709, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2021.